Gotowe bibliografie tematyczne / HR+/HER2− metastatic breast cancer

Spis treści

  1. Artykuły w czasopismach
  2. Rozprawy doktorskie
  3. Książki
  4. Części książek
  5. Streszczenia konferencji
  6. Raporty organizacyjne

Gotowa bibliografia na temat „HR+/HER2− metastatic breast cancer”

Autor: Grafiati
Data publikacji: 2 czerwca 2025
Data aktualizacji: 31 lipca 2025

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „HR+/HER2− metastatic breast cancer”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "HR+/HER2− metastatic breast cancer"

1

Khan, Noman Ahmed Jang, Mahmoud Abdallah, and Maria Tria Tirona. "Hormone Receptor Positive/HER2 Negative Breast Cancer With Isolated Bladder Metastasis: A Rare Case." Journal of Investigative Medicine High Impact Case Reports 9 (January 2021): 232470962110221. http://dx.doi.org/10.1177/23247096211022186.

Pełny tekst źródła
Streszczenie:
Breast cancer is the most common cancer diagnosed in women in North America. Hormone receptor positive (HR+) and HER2 negative (HER2−) breast cancers account for at least 60% to 70% of all breast cancer cases. They usually metastasize to lymph nodes, bones, liver, lungs, and brain. Urinary bladder is a very unusual site for metastatic HR+/HER2− breast cancer and occurs in only 2% of all metastatic disease. In this article, we present a case of a 63-year-old female with locally advanced breast cancer who underwent mastectomy, adjuvant chemotherapy, radiation, and hormonal therapy. She was in re
Style APA, Harvard, Vancouver, ISO itp.
2

Hrizat, A. S., and E. Brachtel. "Proliferation Index in “HER2 Low” Metastatic Breast Cancer." American Journal of Clinical Pathology 160, Supplement_1 (2023): S13—S14. http://dx.doi.org/10.1093/ajcp/aqad150.030.

Pełny tekst źródła
Streszczenie:
Abstract Introduction/Objective There is considerable genetic heterogeneity between primary and metastatic breast cancer. The new classification of the "HER2-low" category includes tumors characterized by a low level of HER2 expression (immunohistochemistry (IHC) score 1+ or 2+ without in situ hybridization (ISH) amplification), in addition to the known HER2 negative (HER2-0) and HER2+ (amplified) cases. The Ki67 proliferation index (PI) can predict breast cancer prognosis. Proliferation changes in metastatic breast cancer and in different HER2 categories are not well delineated in clinical co
Style APA, Harvard, Vancouver, ISO itp.
3

Zhu, Anjie, and Hui-Ping Li. "Abstract PO2-05-13: HER2 status presented an unstable switching from primary to recurrent breast cancer." Cancer Research 84, no. 9_Supplement (2024): PO2–05–13—PO2–05–13. http://dx.doi.org/10.1158/1538-7445.sabcs23-po2-05-13.

Pełny tekst źródła
Streszczenie:
Abstract Background: Breast cancer patients with HER2-2+ expression had heterogeneous characteristic. Treatment decision is of great importance after progression. Objective: We explored patients with HER2-2+ in matched primary or recurrent/metastatic tumor samples from January 2010 to June 2022 in our institute were included to evaluate the evolution from or to HER2-2+ expression. Meanwhile, with an emerging of novel entity as HER2-low expression breast cancer, we included this category when analysis as well. Results: In the cohort of a total of 159 breast cancer patients with HER2-2+ expressi
Style APA, Harvard, Vancouver, ISO itp.
4

Han, Yiqun, Yun Wu, Hangcheng Xu, Jiayu Wang, and Binghe Xu. "The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study." International Journal of Clinical Oncology 27, no. 4 (2022): 707–16. http://dx.doi.org/10.1007/s10147-022-02115-x.

Pełny tekst źródła
Streszczenie:
Abstract Background To investigate the impact of hormone receptor (HR) on the clinicopathological characteristics and prognosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Methods Using the Surveillance, Epidemiology, and End Results database, we enrolled patients diagnosed with HER2-positive breast cancer between 2010 and 2016, which were successively assessed for eligibility and categorized into HR + /HER2 + and HR-/HER2 + subgroups. Clinicopathological characteristics were undergone comparative analyses with the baseline distinctions calibrated by propensity s
Style APA, Harvard, Vancouver, ISO itp.
5

Zhang, Shaohua, Tao Wang, Li Bian, Guohui Han, Xiangdong Bai, and Zefei Jiang. "Abstract P5-10-21: Efficacy and safety of utidelone plus bevacizumab in the treatment of patients with Her2- metastatic breast cancer study." Clinical Cancer Research 31, no. 12_Supplement (2025): P5–10–21—P5–10–21. https://doi.org/10.1158/1557-3265.sabcs24-p5-10-21.

Pełny tekst źródła
Streszczenie:
Abstract Background: Despite the rapid development of targeted therapy and immunotherapy for breast cancer in recent years, Chemotherapy remains an important treatment for metastatic breast cancer (MBC), and currently there is no standard chemotherapy regimen for MBC patients previously treated with taxanes. Utidelone is a new microtubule inhibitor drug developed in China, which has demonstrated excellent efficacy for metastatic breast cancer. Historical studies have shown that chemotherapy combined with angiogenic inhibitors can improve PFS in advanced breast cancer patients compared with che
Style APA, Harvard, Vancouver, ISO itp.
6

Lv, Huimin, Min Yan, Mengwei Zhang, et al. "Abstract PO1-06-05: Heterogeneity and prognostic characteristics of HER2-low breast cancer: A retrospective analysis of patients with HER2-negative metastatic breast cancer." Cancer Research 84, no. 9_Supplement (2024): PO1–06–05—PO1–06–05. http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-06-05.

Pełny tekst źródła
Streszczenie:
Abstract Background: It remains uncertain as to whether low levels of HER2 positivity have any prognostic implications in breast cancer patients, whether HER2 levels can be inconsistent between primary tumors and metastatic lesions in individuals with advanced HER2-negative breast cancer, and how such inconsistencies may impact patient prognosis. Methods: A retrospective analysis of advanced breast cancer patients admitted to our hospital from from January 1st, 2010 to January 1st, 2019 was performed, with all patients that underwent at least one metastatic lesion biopsy being screened. The ho
Style APA, Harvard, Vancouver, ISO itp.
7

Niikura, Naoki, Jun Liu, Naoki Hayashi, et al. "Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors." Journal of Clinical Oncology 30, no. 6 (2012): 593–99. http://dx.doi.org/10.1200/jco.2010.33.8889.

Pełny tekst źródła
Streszczenie:
Purpose We evaluated whether patients with human epidermal growth factor receptor 2 (HER2) –positive primary breast tumors had metastatic tumors that were HER2 positive (concordant) or HER2 negative (discordant). We then evaluated whether treatment with trastuzumab or chemotherapy before biopsy of the metastasis had any effect on the rate of HER2 discordance. We also compared the overall survival durations of patients with HER2-concordant and -discordant tumors. Patients and Methods We retrospectively identified all patients who initially had been diagnosed with HER2-positive (immunohistochemi
Style APA, Harvard, Vancouver, ISO itp.
8

Shin, Junghoon, Ji-Yeon Kim, Jung Min Oh, et al. "Comprehensive Clinical Characterization of Decade-Long Survivors of Metastatic Breast Cancer." Cancers 15, no. 19 (2023): 4720. http://dx.doi.org/10.3390/cancers15194720.

Pełny tekst źródła
Streszczenie:
Background: Elucidating the clinical features of metastatic breast cancer (MBC) patients with an exceptionally favorable prognosis may offer insights to improve the survival of more typical patients. Methods: We collected comprehensive real-world data on clinicopathologic characteristics, treatments, and outcomes of 110 consecutive MBC patients who survived for over ten years from the clinical data warehouse of Samsung Medical Center. Results: The cohort included 54 hormone receptor (HR)-positive/HER2-negative (HR+/HER2−), 21 HR+/HER2+, 16 HR−/HER2+, and 14 triple-negative breast cancer (TNBC)
Style APA, Harvard, Vancouver, ISO itp.
9

Hasan, Shaakir, Zachary Neubauer, Robert H. Press, et al. "Prognostic implications of HER2Neu-low in metastatic breast cancer." Journal of Clinical Oncology 40, no. 16_suppl (2022): 1044. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.1044.

Pełny tekst źródła
Streszczenie:
1044 Background: HER2-Low (or HER2-equivocal, FISH negative) breast cancer has historically been treated as HER2-negative; however, recent evidence suggests that there may be prognostic and/or predictive differences between the two. We explore demographic characteristics and clinical outcomes of HER2-negative and HER2-low metastatic breast cancer (MBC) patients using real world data. Methods: We queried the National Cancer Database to identify MBC patients that were HER2 0, HER2 1+, or HER2 2+ per immunohistochemical staining, with the latter two defined as HER2-low and the former HER2-negativ
Style APA, Harvard, Vancouver, ISO itp.
10

Lucas, Tylan, Joshua Chan, and Neha Chopra. "Sacituzumab Govitecan for the Treatment of HR+/HER2- Breast Cancer in Heavily Pre-treated Patients." Oncology & Haematology 19, no. 1 (2023): 1. http://dx.doi.org/10.17925/ohr.2023.19.1.1.

Pełny tekst źródła
Streszczenie:
Metastatic hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) breast cancer survival outcomes have improved significantly; however, once endocrine resistance develops, response rates to systemic treatments are limited. Within the developing field of antibody–drug conjugates, the TROPiCS-02 study showed a significant improvement in progression-free survival with sacituzumab govitecan compared with physician’s choice of chemotherapy in patients with endocrine-resistant, metastatic, HR+/HER2- breast cancer. Additionally, overall survival similarly improved (
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Rozprawy doktorskie na temat "HR+/HER2− metastatic breast cancer"

1

Hall, Charles. "Ex vivo reprogramming of tumor-reactive immune cells from FVBN202 mice bearing lung metastatic mammary carcinoma: an immunotherapeutic opportunity revealed against recurrence." VCU Scholars Compass, 2013. http://scholarscompass.vcu.edu/etd/3176.

Pełny tekst źródła
Streszczenie:
Metastatic breast cancer treatment has seen few advances in recent years, yet treatment resistance continues to rise, causing disease recurrence. A pilot study was performed to determine the efficacy of ex vivo expansion and reprogramming of tumor-reactive immune cells from experimental metastatic tumor-sensitized mice. Also, phenotypic changes in tumors due to metastasis or tumor microenvironment influences were characterized. Metastatic neu+ mouse mammary carcinoma (mMMC) and its distant relapsing neu-antigen-negative variant (mANV) were investigated in FVBN202 mice. Tumor-reactive central m
Style APA, Harvard, Vancouver, ISO itp.
2

Monteiro, Inês de Paula Costa. "Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies." Master's thesis, 2016. https://repositorio-aberto.up.pt/handle/10216/83769.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Monteiro, Inês de Paula Costa. "Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies." Dissertação, 2016. https://repositorio-aberto.up.pt/handle/10216/83769.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Yeh, Ying-Chih, and 葉盈池. "Effectiveness and Cost-Effectiveness of Trastuzumab Emtansine in Women with HER2-Positive Locally Advanced or Metastatic Breast Cancer: A Systematic Review and Meta-Analysis." Thesis, 2018. http://ndltd.ncl.edu.tw/handle/c8et72.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Šlegerová, Lenka. "Hodnocení zdravotní technologie (HTA): léčba karcinomu prsu, případová studie ČR." Master's thesis, 2019. http://www.nusl.cz/ntk/nusl-392652.

Pełny tekst źródła
Streszczenie:
Health technology assessment: case study on breast carcinoma treatment in the Czech Republic Bc. Lenka Šlegerová January 4, 2019 Abstract This thesis proposes an original method for assessing total costs of med- ical treatment. It defines the semi-Markov model with four states that are associated with specific costs of the treatment, and not with patients' health statuses. This method is applied to individuals' treatment data drawn from the Czech clinical practice in the treatment of the metastatic HER2+ breast cancer. The aim is to assess the cost-effectiveness of adding medication per- tuzum
Style APA, Harvard, Vancouver, ISO itp.

Książki na temat "HR+/HER2− metastatic breast cancer"

1

Oehlrich, Marcus. Recombinant monoclonal antibody trastuzumab for the treatment of metastatic breast cancer with tumors overexpressing the HER2-neu proto-oncogene: A systematic review. dissertation.de, 2003.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Preusser, Matthias, Gabriele Schackert, and Brigitta G. Baumert. Metastatic brain tumours. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199651870.003.0019.

Pełny tekst źródła
Streszczenie:
Brain metastasis is a common clinical challenge in cancer patients, particularly those with lung cancer, breast cancer, and melanoma. The prognosis is poor, with median overall survival times measured in months for most patient populations. Established treatments include neurosurgical resection, radiotherapy (including stereotactic radiosurgery and stereotactic radiotherapy, whole-brain radiotherapy, and new radiation techniques), and supportive care measures. Recently, more and more targeted therapies such as EGFR inhibitors, HER2 antagonists, BRAF inhibitors, ALK inhibitors, and immune check
Style APA, Harvard, Vancouver, ISO itp.
3

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, Gareth Morris-Stiff, and Amen Sibtain. Colorectal cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0015_update_001.

Pełny tekst źródła
Streszczenie:
Breast cancer reviews the epidemiology and aetiology of this malignancy, with particular attention to the genetics underlying familial breast cancer, its pathology along with its receptors, oestrogen receptor (ER), the growth factor receptor HER2, and epidermal growth factor receptor (EGFR), and the bearing these have on treatment and prognosis. The benefits of breast cancer screening in the population and families at higher risk are discussed. Presenting symptoms and signs are followed by investigation including examination, bilateral mammography, and core biopsy of suspicious lesions. Manage
Style APA, Harvard, Vancouver, ISO itp.

Części książek na temat "HR+/HER2− metastatic breast cancer"

1

Kwon, Youngmi, Yunju Kim, Bo Hwa Choi, et al. "HR(−) HER2(+) Breast Cancer." In A Practical Guide to Breast Cancer Treatment. Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-19-9044-1_7.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Lee, Eun Sook, Chan Wha Lee, Youngmi Kwon, Jeayeon Woo, and Yunju Kim. "HR(−) HER2(−) Breast Cancer." In A Practical Guide to Breast Cancer Treatment. Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-19-9044-1_8.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Kim, Yunju, Bo Hwa Choi, Eun-Gyeong Lee, Ji Young You, and Youngmi Kwon. "HR(+) HER2(−) Breast Cancer." In A Practical Guide to Breast Cancer Treatment. Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-19-9044-1_5.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Park, Soojin, Ran Song, Yunju Kim, et al. "HR(+) HER2(+) Breast Cancer." In A Practical Guide to Breast Cancer Treatment. Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-19-9044-1_6.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Imamović, Elma, Anisa Veledar, Zerina Kalić, Adna Softić, Emina Mrđanović, and Merima Smajlhodžić-Deljo. "Impact of PET and PET/CT Radiotracer for Evaluating Efficacy of CDK4/6 Inhibitor Therapy in HR-Positive HER2-Negative Metastatic Breast Cancer." In IFMBE Proceedings. Springer Nature Switzerland, 2024. http://dx.doi.org/10.1007/978-3-031-49062-0_38.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Bayraktar, Soley, and Adnan Aydiner. "Systemic Treatment of HER2-Negative Metastatic Breast Cancer." In Breast Cancer. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-96947-3_22.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Aydiner, Adnan. "Systemic Treatment of HER2-Overexpressing Metastatic Breast Cancer." In Breast Cancer. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-96947-3_23.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Aydiner, Adnan. "Treatment of HER2-Overexpressing Metastatic Breast Cancer." In Breast Disease. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-26012-9_33.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Aydiner, Adnan. "Treatment of HER2-Overexpressing Metastatic Breast Cancer." In Breast Disease. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16792-9_32.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Bayraktar, Soley, and Adnan Aydiner. "Treatment of HER2-Negative Metastatic Breast Cancer: Chemotherapy." In Breast Disease. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16792-9_31.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "HR+/HER2− metastatic breast cancer"

1

Freitas, Paola Ferreira de, Renata Borges de Aquino, Andre Mattar, Jorge Yoshinori Shida, and Luiz Henrique Gebrim. "CASE REPORT: PATHOLOGICAL COMPLETE RESPONSE IN BREAST IN A PATIENT WITH METASTATIC BREAST CANCER TREATED WITH ANASTROZOLE." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2088.

Pełny tekst źródła
Streszczenie:
Background: De novo metastatic breast cancer is seldomly encountered in patients visiting doctor’s clinics for the first time. This article reports a case of cervical/submandibular metastatic breast cancer treated with neoadjuvant endocrine therapy (NET) with anastrozole (ANA). Case description: We herein report on a patient affected by HR+, HER2−, and metastatic breast cancer treated with NET that presented after 6 months with the possibility of breast-conserving surgery due to clinical and radiological complete response, revealing after surgery pathological complete response. Conclusion: Eve
Style APA, Harvard, Vancouver, ISO itp.
2

Xie, J., Y. Hao, N. Li, et al. "Abstract P2-08-20: Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites." In Abstracts: Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.sabcs15-p2-08-20.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Nunes, Mirella Laranjeira, Maria Carolina da Trindade Henriques Assunção, Pryscila Correia de Queiroz e. Silva, et al. "METASTATIC PURE MUCINOUS BREAST CARCINOMA: A CASE REPORT." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2051.

Pełny tekst źródła
Streszczenie:
Introduction: Pure mucinous breast carcinoma (PMBC) is rare, representing about 2% of breast cancers. Histologically, it is defined as having 90% or more of a mucinous component. It usually affects women between the ages of 55 and 60 years. Only 1% occurs in women below 35 years. It usually has positive hormone receptors (HRs); however, the positivity of HER-2 is rare. The management is not well established, being extrapolated from data on invasive ductal carcinoma. It usually presents a favorable prognosis, with rare lymph node (LN) involvement and metastasis rate of less than 15%. HR status
Style APA, Harvard, Vancouver, ISO itp.
4

Dooper, Marten. "OS benefit of sacituzumab govitecan in pre-treated HR-positive/HER2-negative metastatic breast cancer." In ESMO Congress 2022, edited by Stefan Rauh. Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/f0a84142.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Zheng, Kelly F., Kenichi Shimada, Madeline G. Townsend, et al. "896 Characterizing macrophage heterogeneity in HR+/HER2- metastatic breast cancer reveals novel mechanisms of resistance." In SITC 38th Annual Meeting (SITC 2023) Abstracts. BMJ Publishing Group Ltd, 2023. http://dx.doi.org/10.1136/jitc-2023-sitc2023.0896.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Hoskins, Kent F., Paul Richards, and Kari Wisinski. "Abstract 1615: First-line CDK4/6 inhibitor treatment for HR+, HER2-negative metastatic breast cancer (MBC)." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-1615.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Goyal, RK, GC Carter, SN Nagar, et al. "Abstract P5-08-19: Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2– metastatic breast cancer." In Abstracts: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, Texas. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.sabcs16-p5-08-19.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Rugo, H., S. Tolaney, M. Dickler, et al. "Abstract OT2-01-07: A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)." In Abstracts: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, Texas. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.sabcs16-ot2-01-07.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

den Brok, Wendie-Lou D., Caroline Speers, Gondara Lovedeep, Emily Baxter, Scott Tyldesley, and Lohrisch Caroline. "Abstract P6-08-40: Survival of metastatic hormone receptor (HR) positive/HER2 negative; HER2+; and triple negative (TN) breast cancer based on initial presentation." In Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-p6-08-40.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Wander, SA, LM Spring, CR Stein, et al. "Abstract P6-18-39: Abemaciclib after prior palbociclib exposure in patients with metastatic hormone-receptor positive (HR+)/HER2- breast cancer." In Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-p6-18-39.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Raporty organizacyjne na temat "HR+/HER2− metastatic breast cancer"

1

Hu, Wenyu, and Nanlin Li. Pyrotinib for HER2-positive metastatic breast cancer: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.3.0076.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Lyerly, H. K. Rapid Translation of a Novel and Potent Vaccine in HER2+ Metastatic Breast Cancer Patients. Defense Technical Information Center, 2013. http://dx.doi.org/10.21236/ada593925.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Zhang, Xiaohui, Yidong Zhou, Feng Mao, Yan Lin, Songjie Shen, and Qiang Sun. Efficacy and Safety of Anti-HER2 Agents in Combination with Chemotherapy for Metastatic HER2-positive Breast Cancer Patient: A Network Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2020. http://dx.doi.org/10.37766/inplasy2020.9.0086.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Wang, Chuan, Ruiliang Chen, Chuangui Song, Jie Zhang, and Yushuai Yu. Efficacy and safety of neoadjuvant therapy for HR-positive/HER2-negative early breast cancer: a Bayesian network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2024. http://dx.doi.org/10.37766/inplasy2024.4.0092.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany rozszerzonymi bibliografiami na temat „HR+/HER2− metastatic breast cancer” dla poszczególnych typów źródeł:
Artykuły w czasopismach
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii